UNICYCIVE THERAPEUTICS INC (UNCY) Stock Price & Overview
NASDAQ:UNCY • US90466Y2028
Current stock price
The current stock price of UNCY is 6.87 USD. Today UNCY is down by -1.43%. In the past month the price decreased by -0.14%. In the past year, price increased by 16.11%.
UNCY Key Statistics
- Market Cap
- 173.399M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.17
- Dividend Yield
- N/A
UNCY Stock Performance
UNCY Stock Chart
UNCY Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY turns out to be only a medium performer in the overall market: it outperformed 63.49% of all stocks.
UNCY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
UNCY Earnings
UNCY Forecast & Estimates
14 analysts have analysed UNCY and the average price target is 45.46 USD. This implies a price increase of 561.76% is expected in the next year compared to the current price of 6.87.
UNCY Groups
Sector & Classification
UNCY Financial Highlights
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -2.17. The EPS increased by 79.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.21% | ||
| ROE | -192.09% | ||
| Debt/Equity | 0 |
UNCY Ownership
UNCY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.645B | ||
| AMGN | AMGEN INC | 15.27 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.17 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.85 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.86 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.74 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.25 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About UNCY
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Company Info
IPO: 2021-06-17
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 22
Phone: 16503840642
UNICYCIVE THERAPEUTICS INC / UNCY FAQ
What does UNCY do?
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
What is the current price of UNCY stock?
The current stock price of UNCY is 6.87 USD. The price decreased by -1.43% in the last trading session.
What is the dividend status of UNICYCIVE THERAPEUTICS INC?
UNCY does not pay a dividend.
How is the ChartMill rating for UNICYCIVE THERAPEUTICS INC?
UNCY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of UNCY stock?
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 173.40M USD. This makes UNCY a Micro Cap stock.
Can you provide the ownership details for UNCY stock?
You can find the ownership structure of UNICYCIVE THERAPEUTICS INC (UNCY) on the Ownership tab.